Cholesterol

Sarcopenia, a progressive skeletal order that involves the accelerated loss of muscle mass and function, is associated with adverse outcomes such as functional decline, frailty, and mortality.

The results act as a contradiction to conventional wisdom of high-density lipoprotein (HDL) cholesterol being healthy and lowering the risk of heart disease, but more research is warranted.

Compared with other indicators of cardiovascular risk, the ratio of non-high-density lipoprotein cholesterol (HDL-C) to normal HDL-C had a stronger association with the risk of hypertension and heart disease.

This marks the first FDA-approved treatment for this rare lipid storage disease.

There was an association observed between fluctuating low-density lipoprotein cholesterol and the risk of developing dementia and cognitive impairment.

The agency will now review the novel PCSK9 inhibitor for possible approval in patients with or at high risk of atherosclerotic cardiovascular disease.

An inverse relationship was observed between genetic conditions associated with high levels of low-density lipoprotein cholesterol and the risk of developing T2D.

The results highlight hemoglobin A1c/high-density lipoprotein cholesterol as a potential clinical marker for long-term stroke risk.

High-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B did not have significant correlations with chronic obstructive pulmonary disease.

Challenges include therapy gaps, nonadherence, and fragmented care.

This case report depicts a probable infusion reaction in a 61-year-old woman prescribed evinacumab for the treatment of familial hypercholesterolemia.

Regardless of confounding factors, the ratio of high-sensitivity C-reactive protein to high-density lipoprotein cholesterol predicts the all-cause long-term mortality.

Dyslipidemia is a condition in which there are abnormal levels of lipids in the blood stream, including high levels of low-density lipoprotein cholesterol, low levels of high-density lipoprotein cholesterol, and/or high levels of triglycerides.

Patients with acute coronary syndrome who were in the high quartile were at significantly higher risk for major adverse cardiovascular events (MACE).

Lp(a) is a critical risk factor for atherosclerotic cardiovascular disease, but current lipid-lowering therapies are largely ineffective at lowering Lp(a) levels.

Muvalaplin is an oral, small molecule inhibitor that can reduce lipoprotein(a).

High levels of the Oscillibacter genus of bacteria were associated with reduced cholesterol.

Lerodalcibep is a third-generation PCSK9 inhibitor that demonstrated success in reducing low density lipoprotein cholesterol (LDL-C).

Results of the study showed an inverse relationship between BMI and LDL cholesterol changes for those who adopt a low-carbohydrate diet.

Both statins and newer non-statin medications are important in combination to effectively lower atherogenic lipid levels and reduce cardiovascular risk.

Muvalaplin inhibits the formation of Lp(a) by blocking the initial interaction between apolipoprotein(a) and apo(b).

Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.

Familial chylomicronemia syndrome (FCS) currently has no FDA-approved treatment and is associated with an increased risk of acute pancreatitis.

Twice-yearly dosing could significantly improve adherence rates.

Improving collaboration and communication between all members of the health care team is one way to address these challenges.